Bolt Biotherapeutics (BOLT) Profit After Tax (2020 - 2026)

Bolt Biotherapeutics has reported Profit After Tax for 7 years, with the latest figure at -$7.2 million in Q1 2026.

• Quarterly Profit After Tax rose 34.38% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.6 million (up 53.31% YoY) and the FY2025 annual result came in at -$33.4 million, up 47.07% from the prior year.
• Profit After Tax fell to -$7.2 million in Q1 2026 per BOLT's latest filing, from -$6.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$6.6 million in Q4 2025 and troughed at -$23.7 million in Q1 2022.
• A 5-year average of -$15.3 million and a median of -$16.3 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax fell 17.46% in 2024, then soared 59.41% in 2025.
• Over 5 years, Profit After Tax stood at -$18.6 million in 2022, then declined by 0.21% to -$18.6 million in 2023, then advanced by 13.96% to -$16.0 million in 2024, then soared by 58.67% to -$6.6 million in 2025, then fell by 9.24% to -$7.2 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$7.2 million, -$6.6 million, and -$7.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.